Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-01-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
第二届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the second Supervisory Board of the company. It details the meeting attendance, the agenda items discussed, and the voting results on various financial management and guarantee matters. It references other announcements published on the stock exchange website for more detailed information. The document does not contain financial statements or detailed financial data itself but serves as a formal disclosure of board decisions and approvals. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement of board meeting resolutions rather than a full management report, financial report, or other specific filing type.
2023-01-05 Chinese
关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2023 first extraordinary general meeting of shareholders (临时股东大会) for 科兴生物制药股份有限公司. It details the meeting date, voting methods, agenda items (such as reappointment of the audit firm and amendment of the articles of association), registration procedures, and proxy authorization form. There is no financial data or report content included, only the announcement and procedural information for the shareholders' meeting. The document length is 3371 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-01-05 Chinese
自愿披露关于新冠小分子口服药SHEN26胶囊II期临床试验完成全部受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about the completion of patient enrollment in a Phase II clinical trial for a COVID-19 oral drug. It contains no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, and no detailed financial or governance information. The document is short (1221 characters) and serves as a progress update on a clinical trial, which is a regulatory announcement about ongoing research and development activities. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2023-01-02 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司首次公开发行战略配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal verification opinion from a sponsoring institution regarding the listing and circulation of restricted shares following an initial public offering (IPO) on the STAR Market. It references regulatory approvals, share lock-up periods, and compliance with securities laws. The document does not contain financial statements or detailed financial performance data but rather focuses on the compliance and procedural aspects of restricted share circulation post-IPO. It is not an annual report, earnings release, or management discussion. It is also not a simple announcement of a report publication but a detailed verification opinion. This type of document fits best under Regulatory Filings (RNS), which covers compliance documents and regulatory announcements that do not fit other categories.
2022-12-06 Chinese
首次公开发行战略配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares (strategic placement restricted shares) following the company's initial public offering. It details the number of shares becoming tradable after the lock-up period, the shareholders involved, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial performance data but is a formal notice about share circulation. This fits the category of Share Issue/Capital Change announcements, specifically about restricted shares becoming tradable.
2022-12-06 Chinese
自愿披露关于人干扰素 α2b 喷雾剂I期临床试验完成首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about the completion of the first subject enrollment in a Phase I clinical trial for a new drug. It includes details about the drug, regulatory approval, and a risk warning. The document is short (1013 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement of a clinical trial milestone rather than a financial report or regulatory filing related to financial performance. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial compliance. The closest fitting category is Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial progress and risk disclosure, which does not fit other specific categories.
2022-12-06 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.